# A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults

> **NCT04148118** · PHASE1 · COMPLETED · sponsor: **BlueWillow Biologics** · enrollment: 84 (actual)

## Conditions studied

- Anthrax

## Interventions

- **BIOLOGICAL:** BW-1010: 50 µg - sprayer - IN
- **BIOLOGICAL:** BW-1010: 50 µg - pipette - IN
- **BIOLOGICAL:** BW-1010: 100 µg - sprayer - IN
- **BIOLOGICAL:** BW-1010: 100 µg - pipette - IN
- **BIOLOGICAL:** Saline (Placebo) - sprayer - IN
- **BIOLOGICAL:** Saline (Placebo) - pipette - IN
- **BIOLOGICAL:** BioThrax (positive control) - SC

## Key facts

- **NCT ID:** NCT04148118
- **Lead sponsor:** BlueWillow Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-08
- **Primary completion:** 2021-09-02
- **Final completion:** 2021-09-02
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04148118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04148118, "A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04148118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*